Early predictors of functional disability in Guillain–Barré Syndrome

  • Abdulkadir TunçEmail author
Original Article


This study investigated the predictors of prognosis at admission and after the first month in Guillain–Barré syndrome (GBS) patients. This retrospective study used the electronic records of 81 GBS patients. Age, gender, previous GBS history, antecedent febrile illness and presence of cranial nerve dysfunction were recorded. Detailed neurological examinations, routine biochemical and haematological investigations, cerebrospinal fluid (CSF) analysis and electrophysiological studies, GBS subtypes and treatments were assessed. Hughes disability scores (HDSs) were evaluated at the end of the first day and first month. The GBS patient group included 44 male (54.3%) and 37 female (45.7%) patients. The mean age was 52.2 ± 18.5. The mean HDS score was 2.96 at admission and 1.94 at the end of the first month. Plasma sodium, albumin, and CSF protein levels were significantly correlated with low admission HDS scores (p = 0.03, p  = 0.011, p  = 0.036, and p  < 0.001, respectively). Age, plasma sodium, albumin, neutrophil, neutrophil/lymphocyte ratio (NLR) levels, C-reactive protein (CRP) and CSF protein levels were significantly correlated with poor prognosis at the end of the first month (p < 0.05). Concomitant cranial nerve palsies were significantly correlated with low HDS scores (p = 0.011, p = 0.02) but antecedent events were not correlated with functional disability (p = 0.686, p = 0.413). Decreased albumin and sodium levels and increased CSF protein levels indicated poor GBS prognosis. Higher age, elevated NLR, and higher CRP levels indicated worse prognosis at the end of the first month. However, further studies are needed.


Guillain–Barré syndrome Predictors of outcome Hughes disability score Marker 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Van den Berg B, Walgaard C, Drenthen J et al (2014) Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10(8):469–482CrossRefGoogle Scholar
  2. 2.
    Ozdemir HH (2016) Analysis of the albumin level, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio in Guillain–Barré syndrome. Arq Neuropsiquiatr 74(9):718–722CrossRefGoogle Scholar
  3. 3.
    Sahin S, Cinar N, Karsidag S (2017) Are cerebrospinal fluid protein levels and plasma neutrophil/lymphocyte ratio associated with prognosis of Guillain Barré syndrome? Neurol Int 9(2):7032CrossRefGoogle Scholar
  4. 4.
    DiCapua DB, Lakraj AA, Nowak RJ et al (2015) Relationship between cerebrospinal fluid protein levels and electrophysiologic abnormalities in Guillain–Barré syndrome. J Clin Neuromuscul Dis 17(2):47–51CrossRefGoogle Scholar
  5. 5.
    Fokke C, van den Berg B, Drenthen J et al (2014) Diagnosis of Guillain–Barr´e syndrome and validation of Brighton criteria. Brain 137:33–43CrossRefGoogle Scholar
  6. 6.
    Yuki N, Hartung HP (2012) Guillain–Barr´e syndrome. N Engl J Med 366:2294–2304CrossRefGoogle Scholar
  7. 7.
    Rajabally YA, Uncini A (2012) Outcome and its predictors in Guillain–Barre syndrome. J Neurol Neurosurg Psychiatry 83(7):711–718CrossRefGoogle Scholar
  8. 8.
    Walgaard C, Lingsma HF, Ruts L et al (2011) Early recognition of poor prognosis in Guillain–Barre syndrome. Neurology 76:968–975CrossRefGoogle Scholar
  9. 9.
    Verma R, Chaudhari TS, Raut TP et al (2013) Clinico-electrophysiological profile and predictors of functional outcome in Guillain–Barre syndrome (GBS). J Neurol Sci 335(1–2):105–111CrossRefGoogle Scholar
  10. 10.
    Vaishnavi C, Kapoor P, Behura C et al (2014) C-reactive protein in patients with Guillain Barré syndrome. Indian J Pathol Microbiol 57(1):51–54CrossRefGoogle Scholar
  11. 11.
    Sipilä JO, Kauko T, Soilu-Hänninen M (2017) Admission sodium level and prognosis in adult Guillain–Barré syndrome. Int J Neurosci 127(4):344–349CrossRefGoogle Scholar
  12. 12.
    Huang Y, Ying Z, Chen Z et al (2017) Thyroid hormone level is associated with the frequency and severity of Guillain–Barré syndrome. Int J Neurosci 127(10):893–899CrossRefGoogle Scholar
  13. 13.
    Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain–Barré syndrome. Ann Neurol 27:21–24CrossRefGoogle Scholar
  14. 14.
    Hughes RA, Newsom-Davis JM, Perkin GD et al (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2(8093):750–753CrossRefGoogle Scholar
  15. 15.
    Hadden RD, Cornblath DR, Hughes RA et al (1998) Electrophysiological classification of Guillain–Barré syndrome: clinical associations and outcome. Plasma exchange/sandoglobulin Guillain–Barré syndrome trial group. Ann Neurol 44(5): 780–788CrossRefGoogle Scholar
  16. 16.
    Goverman J (2009) Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 9:393–407CrossRefGoogle Scholar
  17. 17.
    Gonzalez-Quevedo A, Carriera RF, O’Farrill ZL et al (2009) An appraisal of blood-cerebrospinal fluid barrier dysfunction during the course of Guillain–Barré syndrome. Neurol India 57:288–294CrossRefGoogle Scholar
  18. 18.
    Brettschneider J, Petzold A, Süssmuth S et al (2009) Cerebrospinal fluid biomarkers in Guillain–Barré syndrome—where do we stand? J Neurol 256:3–12CrossRefGoogle Scholar
  19. 19.
    Kerasnoudis A, Pitarokoili K, Behrendt V et al (2014) Increased cerebrospinal fluid protein and motor conduction studies as prognostic markers of outcome and nerve ultrasound changes in Guillain–Barré syndrome. J Neurol Sci 340(1–2):37–43CrossRefGoogle Scholar
  20. 20.
    Ghabaee M, Jabedari B, Al-E-Eshagh N et al (2010) Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain–Barre syndrome and multiple sclerosis patients. Int J Neurosci 120:301–304CrossRefGoogle Scholar
  21. 21.
    Gilgun-Sherki Y, Melamed E, Offen D (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251:261–268CrossRefGoogle Scholar
  22. 22.
    Di Giuseppe D, Ulivelli M, Bartalini S et al (2010) Regulation of redox forms of plasma thiols by albumin in multiple sclerosis after fasting and methionine loading test. Amino Acids 38:1461–1471CrossRefGoogle Scholar
  23. 23.
    Su Z, Chen Z, Xiang Y et al (2017) Low serum levels of uric acid and albumin in patients with Guillain–Barre syndrome. Medicine (Baltimore) 96(15):e6618CrossRefGoogle Scholar
  24. 24.
    Saifudheen K, Jose J, Gafoor VA et al (2011) Guillain–Barr´ e syndrome and SIADH. Neurology 76:701–704CrossRefGoogle Scholar
  25. 25.
    Wang Y, Liu J (2015) Hyponatremia is a predictor for poor outcome in Guillain–Barr´e syndrome. Neurol Res 37:347–351CrossRefGoogle Scholar
  26. 26.
    Hiew FL, Winer JB, Rajabally YA (2016) Hyponatraemia in Guillain–Barre’ syndrome revisited. Acta Neurol Scand 133:295–301CrossRefGoogle Scholar
  27. 27.
    van Koningsveld R, van Doorn PA, Schmitz PI et al (2000) Mild forms of Guillain–Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 54:620–625CrossRefGoogle Scholar
  28. 28.
    Walgaard C, Lingsma HF, Ruts L et al (2011) Early recognition of poor prognosis in Guillain–Barre ´ syndrome. Neurology 76: 968e75CrossRefGoogle Scholar
  29. 29.
    Seta T, Nagayama H, Katsura K et al (2005) Factors influencing outcome in Guillain–Barré Syndrome: comparison of plasma adsorption against other treatments. Clin Neurol Neurosurg 107(6):491–496CrossRefGoogle Scholar
  30. 30.
    Alan S, Tuna S, Türkoğlu EB (2015) The relation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume with the presence and severity of Behçet’s syndrome. Kaohsiung J Med Sci 31(12):626–631CrossRefGoogle Scholar
  31. 31.
    Berciano J, Figols J, García A et al (1997) Fulminant Guillain–Barré syndrome with universal inexcitability of peripheral nerves: a clinicopathological study. Muscle Nerve 20(7):846–857CrossRefGoogle Scholar
  32. 32.
    Lobo SM (2012) Sequential C-reactive protein measurements in patients with serious infections: does it help? Crit Care 16:130CrossRefGoogle Scholar

Copyright information

© Belgian Neurological Society 2019

Authors and Affiliations

  1. 1.Clinic of Neurology, Sakarya Training and Research HospitalSakarya UniversitySakaryaTurkey

Personalised recommendations